FPAS
ALDX icon

Focus Partners Advisor Solutions’s Aldeyra Therapeutics ALDX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8K Buy
17,026
+6,491
+62% +$28.4K ﹤0.01% 1237
2025
Q4 		$54.6K Sell
10,535
-4,074
-28% -$20.9K ﹤0.01% 1067
2025
Q3 		$75.2K Buy
+14,609
New +$76.2K ﹤0.01% 1104

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Focus Partners Advisor Solutions's ALDX Position: Q1 2026 in Review

Focus Partners Advisor Solutions increased its Aldeyra Therapeutics (ALDX) stake by 62% in Q1 2026, buying an estimated $28.4K and bringing the position to 17,026 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1237.

Focus Partners Advisor Solutions first reported a position in ALDX in Q3 2025 and has held it in 3 quarters since. The position peaked at $75.2K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Focus Partners Advisor Solutions held 17,026 shares of Aldeyra Therapeutics worth $28.8K as of Q1 2026.
  • Focus Partners Advisor Solutions bought 6,491 Aldeyra Therapeutics shares in Q1 2026, an estimated $28.4K.
  • Aldeyra Therapeutics made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #1237 holding.
  • Focus Partners Advisor Solutions first reported a position in Aldeyra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Focus Partners Advisor Solutions's Aldeyra Therapeutics position peaked at $75.2K in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.